Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes

INTRODUCTION: Dapagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, is a promising drug approved for the treatment of type 2 diabetes mellitus (T2DM). However, its cost is an obstacle for use in developing countries like India. Thus, we aimed to analyse the impact on the cost of insuli...

Descripción completa

Detalles Bibliográficos
Autores principales: Sosale, Bhavana, Sosale, Aravind, Bhattacharyya, Arpandev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118242/
https://www.ncbi.nlm.nih.gov/pubmed/27761881
http://dx.doi.org/10.1007/s13300-016-0204-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118242/
https://www.ncbi.nlm.nih.gov/pubmed/27761881
http://dx.doi.org/10.1007/s13300-016-0204-9

Ejemplares similares